Treatment With Recombinant Human Growth Hormone (GH) in Children With Short Stature Secondary to a Long Term Corticoid Therapy

Treatment With Recombinant Human Growth Hormone Genotonorm (Registered) in Children With Short Stature Secondary to a Long Term Corticoid Therapy. A Study of Efficacy and Safety.

• To assess the effect of a long-term treatment by Genotonorm on linear growth in children with short stature receiving steroid therapy
• To assess the effect of a long term treatment with Genotonorm on bone mineralisation
• To assess the effect of a long term treatment with Genotonorm on body composition

This trial terminated on 10-Jun-2011 due to prolonged issues with drug accountability and data collection discrepancies. The decision to terminate was not based on any safety concerns.

Inclusion Criteria:

• Children with juvenile arthritis or nephrotic syndrome
• Before or during puberty

Exclusion Criteria:

• Diabetes Type 1 and 2
• Endocrine disease, except well substituted hypothyroidism